Glaxo fires former Trump vaccine tsar over harassment allegations
GSK
1,647.50p
14:20 25/04/24
GlaxoSmithKline said on Wednesday that it has fired Moncef Slaoui as chair of the board of directors of Galvani, in which it owns a majority stake, amid allegations of sexual harassment.
FTSE 100
8,048.14
14:20 25/04/24
FTSE 350
4,420.01
14:20 25/04/24
FTSE All-Share
4,374.22
14:20 25/04/24
Pharmaceuticals & Biotechnology
22,645.31
14:20 25/04/24
The pharmaceuticals company said Slaoui, who led the Trump administration’s Covid-19 vaccine programme, has been accused of sexual harassment and inappropriate conduct towards an employee.
The misconduct is alleged to have taken place "several years ago" when Slaoui was a Glaxo employee.
Following receipt of a letter containing the allegations, GlaxoSmithKline has immediately initiated an investigation with an experienced law firm.
"The investigation of Dr. Slaoui's conduct substantiated the allegations and is ongoing," it said. "Dr. Slaoui's behaviours are wholly unacceptable. They represent an abuse of his leadership position, violate company policies, and are contrary to the strong values that define GSK's culture. The company expects everyone at GSK to behave in accordance with its values, especially its leaders where its standards are the highest. Sexual harassment and any abuse of leadership position are strictly prohibited and will not be tolerated."